Introduction
A well-characterized function of IAPs is their ability to block cell death. XIAP binds to and inhibits effector caspases and the initiator caspase, caspase-9, and is therefore a direct apoptosis inhibitor 1 . Unsurprisingly, compounds that mimic natural inhibitors of IAPs, such as Smac/DIABLO, were developed as anti-tumor agents. Unlike XIAP, cIAP1 and cIAP2 do not directly inhibit caspases 2 but instead promote pro-survival signaling from TNFR1 complex I and also limit formation of the apoptosis inducing TNFR1 complex II [3] [4] [5] . Several Smac mimetics have been developed and pan-IAP inhibitors were shown to kill tumor cells by causing cIAP1/2 degradation, leading to spontaneous activation of NF-κB and consequent autocrine/paracrine TNF/TNFR1induced cell death signaling [6] [7] [8] [9] .
The observation that Smac mimetics trigger TNF production in certain tumor cells suggests that IAPs regulate cytokines and in some cell types this is critical for proper regulation of cell death. Monocytes and macrophages treated with Smac mimetics die in a TNF/TNFR1-dependent manner that requires RIPK1 signaling 10, 11 . By contrast, single loss of cIAPs or XIAP has been shown to reduce cytokine production after stimulation of NOD1, NOD2, TLRs, , contrary to observations made using Smac mimetics. To add to the confusion, mutations in XIAP have been found in X-linked lymphoproliferative syndrome and in a case study of inflammatory bowel disease For personal use only. on April 14, 2017. by guest www.bloodjournal.org From symptoms 17, 18 , suggesting that inactivity or a lack of XIAP triggers chronic inflammation in vivo.
Death domain containing members of the TNFR superfamily and Pattern Recognition Receptor family members (TLR) can induce not only caspase-dependent apoptosis, but are also able to trigger programmed necrosis, also known as necroptosis, in certain contexts 19 . Stimulation of death receptors or TLRs normally triggers apoptosis, but in the absence of caspase-8 function, this instead elicits RIPK3-dependent necroptosis. RIPK3-dependent phosphorylation of Mixed Lineage Kinase Domain-like protein (MLKL) and PGAM5 were reported to be required for necroptosis induction, and while the subsequent molecular necroptotic signaling events remain unclear, increased mitochondrial fission and reactive oxygen species (ROS) production have been implicated [20] [21] [22] . Smac mimeticmediated IAP depletion causes the formation of a RIPK1, caspase-8 and FADD containing complex that has been named the Ripoptosome 1, [23] [24] [25] [26] that is thought to cause necroptotic cell death. Moreover, recent evidence suggests that TNF production triggered by loss of cIAPs or pharmacological inhibition of caspases is regulated by RIPK1, at least in L929 cells 2, 27 .
We generated gene-targeted mice to determine the role of cIAPs and XIAP in cytokine production in the myeloid lineage. We found that cIAPs and XIAP together suppress the production of multiple cytokines and chemokines, including TNF, thereby regulating the homeostasis and function of mature myeloid cells. In contrast to tumor cells, in which loss of cIAPs alone causes TNF production and TNF/TNFR1 mediated cell killing, combined loss of XIAP as well as cIAPs was required for TNF induction and TNF/TNFR1 mediated killing of macrophages. TNF mRNA production was dependent on RIPK1 and secretion of TNF was dependent on RIPK3. These findings suggest that RIPK1 and RIPK3 regulate cytokine production directly and this function resides upstream of, and distinct from, the role of these two kinases in the induction of necroptosis.
Materials and methods Mice
Mice were maintained in a conventional animal facility and experiments performed according to the guidelines of La Trobe University Ethics committee (09-41B and 09-57B) and WEHI Animal Ethics committee. loxP and FRT sites were introduced into the adjacent cIap1 and cIap2 genes by sequential gene targeting in C57BL/6 derived ES cells [3] [4] [5] 28 . Ubiquitous inactivation of cIAP2 expression was achieved by Flpe transgene (B6;SJL-Tg:F4(ACTFLPe)9205Dym/WEHI) (cIap1
-/-). These mice were intercrossed with transgenic Cre mice, inserted by homologous recombination into the lysozyme M locus (LysM-Cre: B6.129; CB.20-Tg; F6(LysM-Cre)/WEHI) mice [6] [7] [8] [9] 29 ), thus producing animals with myeloid cell-specific inactivation of cIAP1 (cIap1 -/-and TNFR2 -/-mice were originally generated on a 129/SV genetic background and backcrossed to C57Bl/6 mice for at least 8 generations. Tnf -/-and Mlkl -/-mice were generated on a C57BL/6 background 32 . Bone marrow reconstitutions of Ripk1 -/-fetal liver on the C57BL/6.129 background failed to produce over 95% reconstitution efficiency, resulting in the use of fetal livers from timed b  l  o  c  k  e  d  i  n  3  %  g  o  a  t  s  e  r  u  m  ,  p  e  r  m  e  a  b  i  l  i  s  e  d  w  i  t  h  0  .  3  %  T  r  i  t  o  n  X  -1  0  0  a  n  d  s  t  a  i  n  e  d  w  i  t  h   c  l  e  a  v  e  d  c  a  s  p  a  s  e  -3  (  C  e  l  l  S  i  g  n  a  l  i  n  g  T  e  c  h  n  o  l  o  g  y  )  .  I  m  a  g  e  s  w  e  r  e  t  a  k  e  n  u  s  i  n  g  a  W  i  d  e  f  i  e  l  d   L  e  i  c  a  D  M  I  6  0  0  0  w  i  t  h  a  d  i  g  i  t  a  l  c  o  l  o  r  c  a  m  e  r  a  L  e  i  c  a  D  F  C  4  2  0  o  r   Mirax slide scanner with   3  C  C  D  c  o  l  o  u  r  c  a  m  e  r  a and processed using Panoramic Viewer.
Hematopoietic Cell Colony Assays
Single cell suspensions from bone marrow or spleens from newborn pups (day 1-4) were resuspended in 0.3% (w/v) agar and DMEM + 20% FBS at a concentration of 2.5 x 10 4 cells/plate. Cells were incubated with 10 ng/mL recombinant murine (rm) GM-CSF, rm M-CSF or recombinant human G-CSF alone or in combination, in addition to 25 ng/ml rm IL-3, 2 U/mL erythropoietin and 100 ng/mL rm stem cell factor for 7 days at 37°C. On day 7, colonies were fixed and stained for counting.
Blood Cell Analysis
Blood was collected from the retro-orbital plexus into tubes containing potassium ethylenediaminetetraacetic acid (Sarstedt) and analyzed in an Advia 2120 automated hematologic analyzer (Bayer).
Statistical Analysis
Cytokine measurements were assessed individually by t-tests for single genotypes. ANOVA was performed followed by Bonferroni post-tests to compare individual genotypes or conditions.
Results

Combined loss of XIAP and cIAPs in myeloid cells results in inflammation
To determine the effects of selective loss of XIAP and cIAPs in the myeloid lineage in vivo, we generated cIap1 -/-X -/-animals compared to wild-type controls (p< 0.01, G-CSF, M-CSF, TNF and p<0.01, IL-6; Figure 1C ). Of the 23 cytokines assayed in a multiplex format, ten, including IL-12p40, Eotaxin, MCP1 and RANTES, were significantly higher in the c1 LC c2
-/-X -/-mice compared to the control animals (supplemental Figure 1) . Some cytokines and chemokines also appeared to be abnormally elevated in the sera of c2
For personal use only. on April 14, 2017. by guest www.bloodjournal.org From mice, but the loss of all three IAPs caused the greatest increase in the levels of cytokines and chemokines, including IL-1β, G-CSF, M-CSF and TNF. In contrast, mice deficient in a single IAP, whether it was cIAP1, cIAP2, or XIAP, did not display abnormally increased levels of any of the cytokines or chemokines tested (data not shown).
cIAPs and XIAP deletion causes granulocytosis and splenomegaly c1 LC c2 -/-X -/-mice presented with granulocytosis and splenomegaly, characterised by loss of splenic architecture (Figure 2A, 2B and 2C) . In addition to the altered spleen structure, signs of inflammation were observed in liver and lung ( Figure 2C and supplemental Figure 2A ). The enlarged spleen was the result of an increase in cell numbers, particularly Ly6G + neutrophils ( Figure 2D and supplemental Figure 2 -/-X -/-mice was further highlighted by increased numbers of F4/80 + monocyte/macrophage subsets in the spleen, particularly the inflammatory subset ( Figure 2F ). Myeloid populations were sorted and assessed for effective deletion of cIAP1 (supplemental Figure 2C) -/-X -/-mice (supplemental Figure 2D ). This suggests the variation in phenotype may be due to the effectiveness of cIAP1 deletion by lysozyme M cre.
Combined loss of cIAPs and XIAP does not impair myeloid cell differentiation but impairs macrophage survival
To determine the effect of abnormally high cytokine levels on myeloid homeostasis, we examined the numbers of myeloid progenitors in the bone marrow. c1
LC
c2
-/-X -/-mice had substantially reduced numbers of common myeloid and megakaryocyte erythroid progenitors (CMP and MEP, respectively) but not granulocyte macrophage progenitor (GMP) in their bone marrow compared to littermate controls ( Figure 3A and supplemental Figure 3 ).
To determine whether the loss of cIAP2 and XIAP in all tissues contributed to the severe pathology of the c1 Figure 3C ). Consistent with previously published data 10, [20] [21] [22] , treatment with TNF neutralizing antibodies (MP6-XT22) or genetic loss of TNF, TNFR1, but not loss of TNFR2, rendered BMDMs resistant to Smac mimetic induced killing ( Figure 3D ; p<0.001).
However, in contrast to previously published data, we found that the killing of BMDMs required the loss or inhibition of XIAP in addition to blockade or loss cIAP1 and cIAP2, since only XIAP deficient but not wild-type BMDMs were killed by the cIAP1 plus cIAP2 selective Smac mimetic TL32711 (p<0.05, Figure 3E ). In addition, while we found that all (27/27) -/-X -/-mice (data not shown). This suggests that while combined loss of cIAP1-plus-cIAP2 in myeloid cells is sufficient to cause chronic inflammation; complete loss of all three IAPs in the myeloid lineage is required for severe pathology.
Loss of XIAP and cIAPs triggers production of certain cytokines and chemokines independent of TNF and prior to induction of cell death
To investigate whether the increase in cytokines and chemokines triggered by loss or blockade of cIAPs and XIAP might be a secondary consequence of the increased production of TNF, we treated BMDMs from wild-type and Tnf -/-mice with Compound A for 24h. With the exception of MCP1, production of several cytokine/chemokines was dampened compared to wild-type macrophages ( Figure 4A ). These results show that Smac mimetic treatment is sufficient to directly induce production of several inflammatory cytokines, but that autocrine TNF/TNFR1 signaling is necessary for maximal production of most of these cytokines. To determine which cytokines and chemokines were induced independently of cell death, we measured both cell death and cytokine release over time. Lactate dehydrogenase (LDH) release was only detectable 4.5h after the presence of TNF could be detected in supernatants or cell lysates ( Figure 4B and 4C). Interestingly, LDH release also increased in Tnf -/-BMDMs treated with Smac-mimetic at 8h, suggesting that LDH release may not fully correlate with macrophage cell death because Tnf -/-BMDMs do not die in response to Smac mimetic treatment. In wild-type BMDMs, PARP cleavage was detectable within 6h of Smac mimetic treatment and the presence of HMGB1 or cyclophilin A, known damage-associated molecular pattern (DAMP) molecules, could be detected by 4.5-6h but was not limited to wild-type BMDMs (data not shown). Conversely secretion of MCP1, MIP1α and MIP1β could already be detected within 1.5h of Smac mimetic treatment, while IL-10 and KC were only observed at 4.5h ( Figure 4D ). These results show that Smac mimetic treatment induces production of diverse inflammatory cytokines by macrophages prior to cell death.
Loss of RIPK1 or RIPK3 attenuates Smac mimetic induced macrophage killing by limiting TNF production
Because IAPs have been shown to inhibit both caspase-dependent apoptosis as well as RIPK3-mediated necroptosis 25, 35, 36 , we examined the mechanism by which Smac mimetics kill BMDMs. Although the broad-spectrum caspase inhibitor QVD-OPH effectively inhibited Smac mimetic induced caspase-3 activation and PARP cleavage in BMDMs (data not shown), it did not prevent killing; instead it increased the percentage of dead cells ( Figure 5A ). In most cellular systems, the RIPK1 inhibitor Necrostatin (Nec-1) only blocks death receptor (e.g. TNFR1) induced cell death when it is combined with caspase inhibitors 22, 24, 35, 37, 38 . It was therefore surprising that Nec-1 alone completely prevented Smac mimetic killing of BMDMs over a range of 5 -50 µM ( Figure 5A and data not shown). To ensure specificity of Nec-1, we treated Ripk1 +/+ and Ripk1 -/-fetal liver derived macrophages (FLDMs) with Compound A and found no increase in LDH release in RIPK1 deficient macrophages compared to wild-type or increase in percentage of dead cells as measured by propidium iodide uptake ( Figure 5A and data not shown). This data was consistent with previous reports of Smac mimetics inducing necroptotic cell death 10, 11 , but was inconsistent with our observations that cleaved caspase-3 is detectable in inflamed lung and liver histology of c1 To determine whether Smac mimetic induced a solely necroptotic death in macrophages, we examined BMDMs derived from Ripk3 -/-and Mlkl -/-mice. Smac mimetic induced killing of BMDMs was inhibited by loss of RIPK3, however, it was only partially limited by MLKL loss. Furthermore, Compound A induced death of MLKL deficient BMDMs was further reduced by Nec-1 ( Figure 5A ). These results strongly suggested that the kinase activity of RIPK1 has a function in addition to activating a RIPK3/MLKL necroptosis inducing complex. We therefore examined TNF production in Ripk3 -/-and Mlkl -/-mice. Surprisingly, Smac mimetic induced TNF production was markedly reduced in both RIPK1-and RIPK3-deficient BMDMs, whereas Mlkl -/-BMDMs
For personal use only. on April 14, 2017. by guest www.bloodjournal.org From produced similar levels of TNF as wild-type cells. Co-treatment with Nec-1 and Compound A blocked Smac mimetic induced TNF production in wild-type macrophages and even those lacking RIPK3 or MLKL, suggesting the kinase activity of RIPK1 is important for TNF production ( Figure 5D ).
Investigations into TNF induction in wild-type BMDMs revealed that TNF mRNA levels increased ~4-fold within 6 hours of Smac mimetic treatment, while Nec-1 treatment prevented Smac mimetic induced TNF mRNA production ( Figure 5E) . Surprisingly, loss of RIPK3, which significantly limited Compound A induced TNF protein production and secretion ( Figure 5F ), did not reduce induction of TNF mRNA. On the contrary, TNF mRNA levels were ~3-fold higher in Ripk3 -/-BMDMs compared to wild-type BMDMs at 4.5 and 6 hours of Smac mimetic treatment ( Figure 5E ). The addition of Nec-1 was able to abrogate this increase in TNF mRNA in the RIPK3 deficient BMDMs ( Figure 5E ). Addition of Nec-1 and loss of RIPK3 similarly affected Smac mimetic induced production of several other cytokines (supplemental Figure 4 ).
These observations indicate that RIPK1 and RIPK3 but not MLKL exert distinct functions in the stimulation of cytokine production that is triggered by the loss or blockade of cIAP1/2 plus XIAP. Furthermore, the data reveals that the role of RIPK1 and RIPK3 in cytokine production and cell death are distinct processes.
Smac mimetic treatment causes an increase in cytokine levels in vivo and this can be attenuated by loss of TNF or RIPK3
To investigate whether administration of Smac mimetic in vivo recapitulates the c1 LC c2
-/-X -/-inflammatory phenotype and investigate how IAPs repress cytokine production, we injected wild-type, Tnf -/-and Ripk3 -/-mice intra-peritoneally with 20 mg/kg of the monovalent pan-IAP Smac mimetic compound, Abbott11; this dose was previously shown to inhibit tumor growth in a murine xenograft model 39 . In wild-type mice, the levels of IL-12, G-CSF, MCP-1, IL-6 and RANTES all rose within 5 hours ( Figure 6A ). In agreement with our in vitro studies ( Figure 4A and supplemental Figure 4 ), we found that the induction of these cytokines was greatly attenuated in Ripk3 -/-mice and almost absent in Tnf -/-mice ( Figure 6A ). The detection of less cytokines in the serum compared to in vitro ( Figure 4A ) is likely due to the effectiveness of a monovalent vs. bivalent pan-IAP Smac mimetic compound to inhibit cIAPs and XIAP.
To determine whether long-term exposure to Smac mimetics could induce pathological abnormalities similar to those seen in c1 LC c2
-/-X -/-mice, we injected mice intraperitoneally with Abbott11 (20 mg/kg body weight) for two weeks, 5 days on/2 days off. Despite the reduced levels of cytokines detected in the serum of Tnf -/-mice, an increase in spleen size was still seen and was caused by increased splenic granulocytes (Ly6G + ) and macrophages (F4/80 + ). In contrast, increased splenic cell numbers and spleen size was not observed in Ripk3 -/-mice injected with Abbott11 ( Figure 6B , 6C and data not shown). To determine if TNF/TNFR1 mediated cell death of macrophages in the c1 LC c2
-/-X -/-mice was the cause of the disrupted myelopoiesis, we intraperitoneally injected anti-TNF (MP6-XT22, 10mg/kg) for three weeks, three times per week from three weeks of age. After anti-TNF injection, c1 LC c2
-/-X -/-mice had a decreased number of granulocytes and 1 0 inflammatory monocytes compared to untreated c1 Figure 6D ). This suggests that production of TNF is a major player in disrupting myelopoeisis but the splenomegaly seen in c1 LC c2
-/-X -/-mice may be due to additional cytokines either induced by TNF and cell death or directly by the loss of IAPs in the myeloid compartment.
Discussion
Our study demonstrates that cIAPs and XIAP cooperate in vivo to limit production of pro-inflammatory cytokines by myeloid cells and thereby prevent death of macrophages. While some c1 LC c2
-/-mice presented with a phenotype comparable to that of c1
mice, many were indistinguishable from littermate wild-type controls based on weight and stature. The combined loss of XIAP, cIAP1 and cIAP2 in the myeloid lineage was required to produce high levels of inflammation, accompanied by granulocytosis and extramedullary hematopoiesis. This suggests either that IAPs have overlapping physiological roles or that they regulate the same pathway(s), but at distinct steps of myeloid differentiation. In addition, it suggests the most influential physiological role IAPs play is in regulating cytokine production. Injection of monovalent pan IAP blocking Smac mimetic compound, Abbott11 39 was well tolerated in the mice at 20 mg/kg for single or multiple injections. An increase in the concentration of pro-inflammatory cytokines ensued 5 hours post Smac mimetic injection, but after 24 hours the levels of cytokines returned to baseline (data not shown). In addition, examination of myelopoiesis following repeated injections of Abbott11 revealed splenomegaly ( Figure 6B ) and abnormalities in hematopoiesis, suggesting that long term treatment of a pan IAP Smac mimetic compound may lead to inflammatory consequences akin to that observed in c1 LC c2
-/-X -/-mice. The IAP selective Smac mimetic, TL32711 that targets cIAP1 and 2, only caused death in BMDMs deficient in XIAP leaving wild-type BMDMs viable. Therefore, this suggests that a selective Smac mimetic compound would be better tolerated but it remains to be seen if these compounds will retain significant antitumour activity in vivo.
1
Our results show that combined loss of cIAP1/2 as well as XIAP causes an abnormal increase in cytokine/chemokine production and not all the effects seen in vivo can be rescued by loss of TNF ( Figure 6 ). Our findings agree with Kearney et al. 16 , that cIAPs and XIAP directly regulate other cytokines in addition to TNF. We recently found that in LPS primed macrophages, cIAP1/2 and XIAP inhibit NLRP3-caspase-1 inflammasome and caspase-8 activation of IL-1β 40 . In contrast to the essential role of RIPK1 kinase activity for TNF production upon IAP removal, LPS and Smac mimetic induced activation of IL-1β was not blocked by Nec-1 or TNF deficiency 40 . IL-1β was detected in the sera of c1 LC c2
-/-X -/-mice and supernatants of Smac mimetic treated wild-type BMDMs, but this appears to be a consequence of TNF production and/or macrophage cell death, as Smac mimetic induced IL-1β secretion was severely reduced from TNF deficient macrophages.
Our data supports the model whereby RIPK1 and RIPK3 can facilitate the production of multiple cytokines, independent of its role in necroptosis. This is further emphasized by the observation that upon Smac mimetic treatment, MLKL deficient BMDMs upregulated TNF comparable to wild-type BMDMs ( Figure 5D ). This alternative role of RIPK1 and RIPK3 may be critical for amplifying the necroptotic pathway. Therefore, the ability of genetic loss of RIPK1 or RIPK3 to prevent the embryonic lethality and chronic inflammation caused by systemic or tissue selective deletion of FADD or caspase-8 [41] [42] [43] might in part be due to loss of a cytokine signaling amplification loop that depends on the RIP kinases rather than solely being a consequence of a block in necroptotic signaling.
The survival defect of cIAPs and XIAP deficient macrophages, production of cytokines and the disruption in myeloid homeostasis caused by loss of cIAPs and XIAP, is reminiscent of the consequences of caspase-8 or FLIP loss in the myeloid lineage. , suggesting that loss or inhibition of caspase-8 can cause production of cytokines in certain cell types. Loss of RIPK3 rescued the ability of caspase-8 deficient myeloid progenitors to differentiate into macrophages 37 , and in our experiments, loss of RIPK3 attenuated cytokine production and exacerbated hematopoiesis caused upon Smac mimetic treatment in vivo. Interestingly, a cytosolic complex consisting of caspase-8, FADD, FLIP and RIPK1 was found in U937 cells driven to differentiate by M-CSF and in these cells, cleavage of RIPK1 and FLIP by caspase-8 reduced NF-κB signalling 46 . Collectively, these and our results suggest that cIAPs and XIAP negatively regulate the formation of the signaling complex that contains caspase-8, FADD, FLIP, RIPK1 and possibly RIPK3. This complex then signals to regulate cytokine/chemokine production in macrophage differentiation. Thus in X-linked lymphoproliferative syndrome 17, 47 or where cIAPs are degraded due to extracellular [48] [49] [50] , IAPs regulate cytokine production through a RIPK1/RIPK3 dependent manner. J.E.V. and K.E.L. are funded by . Apoptosis and not necroptosis is triggered by combined loss of cIAPs and XIAP and is dependent on RIPK1, which is critical for tnf transcription, and RIPK3, which is required for TNF secretion. A) BMDMs of the genotypes indicated were treated for 24h with either of the following compounds alone or in combination: the RIPK1 inhibitor Nec-1 (50 μM), the broad spectrum caspase inhibitor QVD-OPH (10 µM) and the Smac mimetic (Comp. A, 500 nM). The percentages of dead cells were determined by staining with PI followed by flow cytometric analysis. Fetal liver derived macrophages (FLDM) from Ripk1 +/+ and Ripk1 -/-embyros were similarly treated with the exception of Necrostatin (Nec1: 5 µM). LDH release was measured in supernatants 24h after treatment. B) Cleaved caspase-3 detected in lung histology of c1 . RIPK3 is essential for the cytokine production and ensuing granulocytosis that are caused by the combined loss of cIAPs and XIAP. A) WT mice were either left untreated (-) or injected i.p. (+) with the Smac mimetic compound, Abbott11 (20 mg/kg body weight). After 5h, the levels of the cytokines and chemokines indicated were measured by multiplex. B) and C) Mice of the genotypes indicated were either left untreated (-) or injected i.p. (+) with the Smac mimetic compound Abbott11 (20 mg/kg body weight) for 2 weeks (daily for 5 days, then 2 days rest). B) The ratios of the spleen weight to total body weight of the mice after injection of Abbott11 were compared to the ratios from untreated control animals. C) 
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